Mundipharma K.K.
Quick facts
Marketed products
Phase 3 pipeline
- Pralatrexate injection · Oncology
Pralatrexate is a folate analog that inhibits dihydrofolate reductase and other folate-dependent enzymes, disrupting DNA synthesis and cell division in rapidly dividing cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: